

February 2, 2009
Shionogi & Co., Ltd.

**Shionogi announces it has entered into a licensing agreement on
Peptide vaccines for cancer treatment with OncoTherapy Science, Inc.**

Osaka, February 2, 2009 -- Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi) announced today that it has entered into a licensing agreement on Peptide vaccines for cancer treatment with OncoTherapy Science, Inc (“OTS”) (Head Office: Kawasaki; President and CEO: Kensuke Tomita) on February 2, 2009.

Under the agreement, Shionogi obtained a globally exclusive right to develop, manufacture and commercialize OTS’s therapeutic Peptide vaccines derived from 2 kinds of oncoantigens for urinary bladder cancer and 3 kinds of oncoantigens for both esophageal cancer and squamous cell cancers of lung and bronchial tubes as well as head and neck area.

OTS conducts identification and analysis on genes with an important role for development and progression of cancer, based on the information on gene expression of various cancers, which it got through collaborative research with Institute of Medical Science, the University of Tokyo. OTS has identified many Peptide vaccines resulting from selecting appropriate proteins for drug discovery and conducting research on Peptide vaccines building up specific immune function.

Shionogi expects the Company will be able to broaden treatment options for cancer patients and medical experts and make a contribution to meet the great unmet needs of cancer treatment by developing and launching the products as quickly as possible.

For Reference:

About OncoTherapy Science, Inc

Foundation: April 6, 2001

Chief Executives: Kensuke Tomita, President and CEO

Head Office: Kanagawa Science Park R&D D11F, 3-2-1 Sakado,
Takatsu-ku, Kawasaki City, Kanagawa 213-0012
Japan

Description of Business: Research on genes and gene products, and research on diseases that involve gene and gene products.
Development of the treatment of the diseases
and sales of the achievement brought from research
and development.

For further information:

Shionogi & Co., Ltd., Corporate Communications Department

Tel: +81-6-6209-7885 Fax: +81-6-6229-9596